SCHEMBL20076080

SCHEMBL20076080

COC(=O)c1cc(Br)cc(OC)c1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
POLB P06746 3/20 0.47
GAA P10253 3/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 5/20 0.42
FAAH O00519 2/20 0.42
CNR2 P34972 1/20 0.42
ERN1 O75460 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
GFER P55789 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NR4A2 P43354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31198748 1.00 KDM4E (0.47) KDM4EPOLBGAARECQLHSD17B10
SCHEMBL21616730 0.89 ERN1 (0.46) KDM4EPOLBGAARECQLFAAH
SCHEMBL24379436 0.83 ULK1 (0.39) KDM4EPOLBGAARECQLHSD17B10
SCHEMBL12957471 0.82 KDM4E (0.47) KDM4EPOLBGAARECQLHSD17B10
SCHEMBL23294024 0.82 KDM4E (0.56) KDM4EPOLBGAAHSD17B10FAAH
SCHEMBL1620851 0.82 FAAH (0.55) KDM4EPOLBGAAHSD17B10FAAH
SCHEMBL2024646 0.82 CYP3A4 (0.49) KDM4EPOLBGAARECQLERN1
SCHEMBL29927434 0.82 CYP3A4 (0.49) KDM4EPOLBGAARECQLERN1
SCHEMBL1004632 0.81 KDM4E (0.58) KDM4EPOLBGAAHSD17B10FAAH
SCHEMBL20397117 0.81 KDM4E (0.46) KDM4EPOLBGAAHSD17B10FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS INC (US) 2025-11-27 US disclosed
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same ARVINAS OPERATIONS, INC. (US) 2025-03-04 US disclosed
EP-4509184-A2 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2025-02-19 EP disclosed
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2025-01-30 US disclosed
EP-3526202-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2025-01-08 EP disclosed
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-09-03 US disclosed
CN-118480030-A Cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-08-13 CN disclosed
CN-112262134-B Cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-05-24 CN disclosed
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-23 US disclosed
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-09 US disclosed
CN-111892577-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2020-11-06 CN disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 US disclosed
US-20200155689-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 US disclosed
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2020-03-26 US disclosed
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor Arvinas, Inc. (US) 2020-03-10 US disclosed
WO-2019199816-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2019-10-17 WO disclosed
WO-2018071606-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. (US) 2018-04-19 WO disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360219-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 KDM4E 1613/4885POLB 4089/4885GAA 1175/4885
US-12239711-B2 Cereblon ligands and bifunctional compounds comprising the same CRBN, CBL, MDM2 KDM4E 1613/4885POLB 4089/4885GAA 1175/4885
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 713/4885POLB 3165/4885GAA 1094/4885
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 713/4885POLB 3165/4885GAA 1094/4885
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 706/4885POLB 3138/4885GAA 1082/4885
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 706/4885POLB 3138/4885GAA 1082/4885
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 KDM4E 1613/4885POLB 4089/4885GAA 1175/4885
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 706/4885POLB 3138/4885GAA 1082/4885
US-20200155689-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 KDM4E 1613/4885POLB 4089/4885GAA 1175/4885
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 713/4885POLB 3165/4885GAA 1094/4885
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 713/4885POLB 3165/4885GAA 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.